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etter to the Editoras
adriamycin, vincristine and prednisone).rimary  breast  lymphoma:  a c
ear Editor,
rimary breast lymphoma (PBL) is a clinicopathological entity
haracterized by the appearance of a unilateral breast mass
f months of evolution, infrequently accompanied by signs
f skin edema, retraction, erythema and nipple involvement.
his rare situation is especially observed during pregnancy
r postpartum, suggesting that tumor growth is inﬂuenced
y hormonal stimulation, although its association with other
rocesses such as antecedent autoimmune diseases have
een documented.1
We  report the case of a 46-year-old female, with no medi-
al history of interest, who  consulted due to the appearance
f a 4-cm tumor in the left breast of six months of evolution.
e proceeded with the study, making radiological imaging
mammogram and magnetic resonance) and histopatholog-
cal investigations. The examinations conducted, includingPlease cite this article in press as: Herráez-Albendea MM, et al. Primary
http://dx.doi.org/10.1016/j.bjhh.2016.09.011
lood count, biochemistry, serologies, and tumor markers,
ere normal highlighting slightly elevated 2-microglobulin
evels (2.9 mg/L). Mammography and magnetic resonance
Figure 1 – The tumor cells are positive for CD20, CD10, BCL2e  report
ﬁndings were suggestive of breast cancer. Histological exam-
ination showed a tumor composed of a large-sized cell
inﬁltrate, with scarce cytoplasm, irregular nuclear membrane,
split cells with prominent nucleoli, and numerous mitoses.
The immunohistochemical study showed positivity for tumor
populations CD19, CD20, CD79a, PAX-5, bcl-2, bcl-6 and MUM-
1 and focally for CD10 and negativity for cyclin D1 and CD38
(Figure 1). Ki 67 was 80%. Given the combination of clini-
cal, histopathological, and immunohistochemical ﬁndings, a
diagnosis of primary diffuse large B-cell non-Hodgkin lym-
phoma was established, warranting an extended study with
a cervico-thoraco-abdomino-pelvic scan and bone marrow
biopsy to rule out lymphadenopathies and bone marrow
inﬁltration. With the diagnosis of primary diffuse large B-
cell non-Hodgkin lymphoma, chemotherapy was established
using the R-CHOP scheme (rituximab, cyclophosphamide, breast lymphoma: a case report. Rev Bras Hematol Hemoter. 2016.
, BCL6 and MUM1.  Original magniﬁcation images 200×.
PBL is a rare entity in everyday medical practice. Initially
described by Gross in 1880, it is about 0.4–0.5% of all malignant
breast tumors and 0.38–0.70% of non-Hodgkin lymphomas,2
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Figure 2 – Left craniocaudal mammogram of the breast in a
patient with primary breast lynphoma showing a round,
r
1
2
3dense mass.
with the most common subtype being diffuse large B-cell
non-Hodgkin lymphoma. It is characterized by the appear-
ance of a unilateral breast mass particularly in the upper
quadrant of the right side. The incidence increases withPlease cite this article in press as: Herráez-Albendea MM, et al. Primary
http://dx.doi.org/10.1016/j.bjhh.2016.09.011
age. Patients with PBL infrequently present with signs of
skin edema, retraction, erythema, and nipple involvement.
Although its etiology is unknown, its association with differ-
ent processes, among which are estrogen and autoimmune 0 1 6;x  x x(x x):xxx–xxx
diseases,3 has been described; none of these associations were
found in our patient. Other entities that present with similar
breast swelling and symptoms should be considered in the
differential diagnosis. To do this, clinicians rely on a detailed
anamnesis, and complementary analytical and imaging stud-
ies (Figure 2). The diagnosis, regardless of the clinical data
provided by the patient and the exclusion of other entities, is
established when a consistent histological pattern is demon-
strated.
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